Individual genes impact on effectiveness of smallpox vaccination
Research finds effectiveness of smallpox vaccine is down to genes.
A person's individual genetic make-up appears to dictate their response to the smallpox vaccination and how effective it is for them.
That is according to research from the Mayo Clinic, which found the quality of the vaccination is not the only important factor to consider when examining its effectiveness.
Researchers used sophisticated genomic screening for the findings, with some 44 participants who had received the smallpox vaccine in the previous 48 months involved in the study.
Two samples were prepared from each candidate: one that was uninfected and the second that was infected with a smallpox-like virus - vaccinia.
Genetic differences were found between people with greater immunity from smallpox and those with less protective antibodies.
Director of the Mayo Clinic Vaccine Research Group Dr Gregory Poland explained how this development could pave the way for new vaccines to benefit non-responders.
Smallpox, which results in about one in three fatalities, was declared eradicated worldwide in 1980 but still poses a threat in biological warfare.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...